Peritumoral edema shown by MRI predicts poor clinical outcome in glioblastoma

BackgroundMagnetic resonance imaging (MRI) plays an irreplaceable role in the preoperative diagnosis of glioma, and its imaging features are the base of making treatment decisions in patients with glioma, but it is still controversial whether peritumoral edema shown by MRI from preoperative routine scans are associated with patient survival. The aim of this study was to assess the prognostic value of preoperative MRI features in patients with glioblastoma.MethodsA retrospective review of 87 patients with newly diagnosed supratentorial glioblastoma was performed using medical records and MRI data from routine scans. The Kaplan-Meier method and COX proportional hazard model were applied to evaluate the prognostic impact on overall survival of pretreatment MRI features (including peritumoral edema, edema shape, necrosis, cyst, enhancement, tumor crosses midline, edema crosses midline, and tumor size).ResultsIn addition to patient age, Karnofsky performance status (KPS) and postoperative chemoradiotherapy, peritumoral edema extent and necrosis on preoperative MRI were independent prognostic indicator for poor survival. Furthermore, patients with two unfavorable conditions (major edema and necrosis) had a shorter overall survival compared with the remainder.ConclusionsOur data confirm that peritumoral edema extent and necrosis are helpful for predicting poor clinical outcome in glioblastoma. These features were easy to determine from routine MRI scans postoperatively and therefore could provide a certain instructive significance for clinical activities.

[1]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[2]  K. Fujii,et al.  Pathological and clinical features of cystic and noncystic glioblastomas , 2006, Brain Tumor Pathology.

[3]  S. Saikali,et al.  Pathophysiology of glioma cyst formation. , 2006, Medical hypotheses.

[4]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[5]  G. Maira,et al.  Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme , 2008, Cancer.

[6]  P. Pantano,et al.  Supratentorial glioblastoma: Neuroradiological findings and survival after surgery and radiotherapy , 1996, Neuroradiology.

[7]  M. Campone,et al.  Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. , 2009, Current molecular pharmacology.

[8]  [Effect of brain edema on the recurrence pattern of malignant gliomas]. , 1998, Der Radiologe.

[9]  Robert C. Rostomily,et al.  The cause of death in patients with glioblastoma is multifactorial: , 1991, Journal of Neuro-Oncology.

[10]  H. Zhen,et al.  Targeting role of glioma stem cells for glioblastoma multiforme. , 2013, Current medicinal chemistry.

[11]  Daniel J Brat,et al.  Pseudopalisades in Glioblastoma Are Hypoxic, Express Extracellular Matrix Proteases, and Are Formed by an Actively Migrating Cell Population , 2004, Cancer Research.

[12]  Y. Shibamoto,et al.  Supratentorial low‐grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables , 1993, Cancer.

[13]  Paul S Mischel,et al.  MR imaging correlates of survival in patients with high-grade gliomas. , 2005, AJNR. American journal of neuroradiology.

[14]  W. Cavenee,et al.  Heterogeneity maintenance in glioblastoma: a social network. , 2011, Cancer research.

[15]  Akio Asai,et al.  Morphological and flow cytometric analysis of cell infiltration in glioblastoma: a comparison of autopsy brain and neuroimaging , 2010, Brain Tumor Pathology.

[16]  T. Cloughesy,et al.  Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma , 2012, American Journal of Neuroradiology.

[17]  Raymond Sawaya,et al.  Prognostic significance of preoperative MRI scans in glioblastoma multiforme , 2004, Journal of Neuro-Oncology.

[18]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[19]  Susan M. Chang,et al.  A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival. , 2011, Journal of neurosurgery.

[20]  R. Dahlrot.  The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. , 2014, Danish medical journal.

[21]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[22]  A. Aguzzi,et al.  Angiogenesis in Transgenic Models of Multistep Carcinogenesis , 2004, Journal of Neuro-Oncology.

[23]  Zhiqiang Li,et al.  Microarray analysis of the hypoxia-induced gene expression profile in malignant C6 glioma cells. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[24]  Zhi-xiong Lin,et al.  Pre-Operative Peritumoral Edema and Survival Rate in Glioblastoma Multiforme , 2013, Oncology Research and Treatment.

[25]  Zhi-xiong Lin.  Glioma-related edema: new insight into molecular mechanisms and their clinical implications , 2013, Chinese journal of cancer.

[26]  C. Sarkar,et al.  A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival , 2011, Journal of Clinical Neuroscience.

[27]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[28]  Raymond Sawaya,et al.  Cystic glioblastoma multiforme: survival outcomes in 22 cases. , 2004, Journal of neurosurgery.

[29]  H. Reulen,et al.  A computed tomography study on formation, propagation, and resolution of edema fluid in metastatic brain tumors. , 1990, Advances in neurology.

[30]  M. Nair,et al.  Conservative surgery and radiotherapy in the treatment of spinal cord astrocytoma , 1997, Journal of Neuro-Oncology.

[31]  W. Wick,et al.  Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma , 2011, BMC Cancer.

[32]  Daniel J Brat,et al.  'Pseudopalisading' Necrosis in Glioblastoma: A Familiar Morphologic Feature That Links Vascular Pathology, Hypoxia, and Angiogenesis , 2006, Journal of neuropathology and experimental neurology.

[33]  Jan C Buckner,et al.  Factors influencing survival in high-grade gliomas. , 2003, Seminars in oncology.

[34]  William D. Dunn,et al.  MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. , 2013, Radiology.

[35]  K. Aldape,et al.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[36]  Chang-fu Zhou,et al.  Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme: A Systematic Review , 2014, Cancer investigation.

[37]  L. Bozzao,et al.  Radiological assessment of necrosis in glioblastoma: variability and prognostic value , 1998, Neuroradiology.

[38]  J. Martinez-Climent,et al.  Cellular Plasticity Confers Migratory and Invasive Advantages to a Population of Glioblastoma‐Initiating Cells that Infiltrate Peritumoral Tissue , 2013, Stem cells.

[39]  Tzong-Shiue Yu,et al.  A restricted cell population propagates glioblastoma growth after chemotherapy , 2012 .

[40]  H. Heinzl,et al.  Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma? , 2009, European journal of neurology.

[41]  A. Ullrich,et al.  Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. , 1993, Cancer research.